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Abstract 
Background: The beneficial effects of statin and renin–angiotensin system inhibitor (RASI) 
are well-known. In this retrospective cohort study,  2-year clinical outcomes were compared 
between monotherapy and combination therapy with statin and RASI in ST-segment 
elevation myocardial infarction (STEMI) patients after stent implantation.  
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Methods: A total of 17,414 STEMI patients were enrolled and divided into the three groups 
(group A: 2448 patients, statin alone; group B: 2431 patients, RASI alone; and group C: 
12,535 patients, both statin and RASI). The principal clinical endpoint was the occurrence of 
major adverse cardiac events (MACEs) defined as all-cause death, recurrent myocardial 
infarction, and any repeat revascularization.  
Results: After adjustment, the cumulative incidences of MACEs in group A (adjusted hazard 
ratio [aHR] 1.337; 95% confidence interval [CI] 1.064–1.679; p = 0.013) and in group B 
(aHR 1.375; 95% CI 1.149–1.646; p = 0.001) were significantly higher than in group C. The 
cumulative incidence of all-cause death in group A was significantly higher than that in group 
C (aHR 1.539; 95% CI 1.014–2.336; p = 0.043). The cumulative incidences of any repeat 
revascularization (aHR 1.317; 95% CI 1.031–1.681; p = 0.028), target lesion vascularization, 
and target vessel vascularization in group B were significantly higher than in group C.  
Conclusions: A Statin and RASI combination therapy significantly reduced the cumulative 
incidence of MACEs compared with a monotherapy of these drugs. Moreover, the 
combination therapy showed a reduced all-cause death rate compared with statin 
monotherapy, and a decreased repeat revascularization rate compared with RASI 
monotherapy. 
Key words: ST-segment elevation Myocardial infarction, statin, renin–angiotensin 
system, long-term outcome 
 
 
Introduction 
Through the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase activity, statin plays essential roles in primary and secondary prevention of adverse 
cardiovascular events [1–3]. The European guidelines recommend starting high-intensity 
statin therapy as early as possible, unless contraindicated, and maintain it long-term in 
patients with ST-segment elevation myocardial infarction (STEMI) (Class 1A) [4]. Similarly, 
the American guidelines recommend the use of early high-intensity statin therapy and should 
be continued in all STEMI patients (Class 1B) [5]. Renin–angiotensin system inhibitors 
(RASI) are beneficial for reducing mortality in STEMI patients after percutaneous coronary 
intervention (PCI) [6], and RASI is recommended in the current guidelines as Class 1A [4, 5]. 
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Even though the beneficial effects of statin and RASI are well-known, results focused on the 
comparative efficacy of combination therapy of statin and RASI, including an angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and statin, or 
RASI monotherapy on the occurrence of major adverse cardiac events (MACEs) during a 
long-term follow-up period in patients with STEMI who underwent successful stent 
implantation are limited. In this study, we investigated the difference in clinical outcome 
parameters between this combination therapy and monotherapy in STEMI patients after 
successful stent implantation, during a 2-year clinical follow-up period.  
 
Methods 
Study design and population 
The Korea Acute Myocardial Infarction Registry (KAMIR) is a nationwide, 
prospective, multicenter registry in South Korea, established in November 2005. The KAMIR 
provides the public and physicians in the “real-world” clinical practice with the demographic 
characteristic and treatment strategies of the acute myocardial infarction (AMI) in Korea [7]. 
The present study is a non-randomized, multicenter, observational, retrospective cohort study. 
A total of 24,549 STEMI patients in KAMIR from November 2005 to June 2015 were 
evaluated. Among them, patients who had the following conditions were excluded: (1) 
incomplete laboratory results (n = 4825, 19.7%), (2) lost to follow-up (n = 984, 4.0%), (3) 
statin or RASI had not been prescribed (n = 1384, 5.6%). After exclusion, a total of 17,414 
STEMI patients who underwent successful stent implantation and who had been prescribed 
statin or RASI were enrolled. The patients were classified into group A (2448, 14.1%), group 
B (2431, 13.9%), and group C (12,535, 72.0%), and received statin alone, RASI alone, or 
both statin and RASI, respectively, as treatment (Fig. 1). The beneficial roles of statin and 
RASI in STEMI [4, 5] are well-known. For these reasons, patients who had not been 
prescribed these drugs in this study were excluded. The data collection was done via a web-
based case report form, at each participating center; well-trained coordinators participated in 
data collection. The study protocol was approved by the ethics committee at each 
participating center and the Chonnam National University Hospital Institutional Review 
Board (IRB) ethics committee (CNUH-2011-172) according to the ethical guidelines of the 
1975 Declaration of Helsinki. All patients provided written informed consent prior to 
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enrollment. All the 17,414 patients completed a 2-year clinical follow-up through face-to-face 
interviews, phone calls, or chart review. 
 
PCI procedure and medical treatment 
Diagnostic coronary angiography and PCI were performed through the femoral and 
the radial artery approach according to the standard technique [8]. Before PCI, all patients 
were given loading doses of 200 to 300 mg acetylsalicylic acid (ASA) and 300 to 600 mg 
clopidogrel, when available; alternatively, 180 mg ticagrelor or 60 mg prasugrel was given. 
The recommended total duration of dual antiplatelet therapy (DAPT, the combination of ASA 
[100 mg/day] with clopidogrel [75 mg/day] or ticagrelor [90 mg twice a day] or prasugrel [5–
10 mg/day]) was more than 12 months to patients who had undergone PCI. Triple antiplatelet 
therapy (TAPT, 100 mg cilostazol, twice a day added on to DAPT) was left to the discretion 
of the individual operators. The statins and their doses were as follows: 10–40 mg of 
atorvastatin, 5–10 mg of rosuvastatin, 2–4 mg of pitavastatin, 10–40 mg of simvastatin, 10–
40 mg of pravastatin, 80 mg fluvastatin, and 50–100 mg lovastatin per day. The RASI used 
and their doses were as follows: 12.5–75 mg of captopril, 2.5–10 mg of ramipril, 2–8 mg of 
perindopril, 1.25–5 mg of cilazapril, 5–10 mg of imidapril, 7.5–15 mg of moexipril, 2.5–10 
mg of enalapril, 5–10 mg of lisinopril, 10 mg of fosinopril, 3.75–7.5 mg of zofenopril, 25–
100 mg of losartan, 150–300 mg of irbesartan, 40–160 mg of valsartan, 40–80 mg of 
telmisartan, 10–20 mg of olmesartan, 4–32 mg of candesartan, 600 mg of eprosartan, and 30–
120 mg of fimasartan per day. 
 
Study definitions and clinical outcomes  
ST-segment elevation myocardial infarction was defined as the patient who had 
experienced chest pain with ST-segment elevation ≥ 2 mm in ≥ 2 contiguous precordial lead, 
or 1 ≥ 1 mm in ≥ 2 limb leads, or new-onset left bundle branch block on the admission 
electrocardiogram [5]. The major clinical endpoint was the occurrence of MACEs, defined as 
all-cause death, recurrent myocardial infarction (Re-MI), any repeat coronary 
revascularization, including target lesion revascularization (TLR), target vessel 
revascularization (TVR), and non-TVR during the follow-up period. All-cause death was 
classified as cardiac (CD) or non-CD. Re-MI was deﬁned as the presence of clinical 
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symptoms, electrocardiographic changes, or abnormal imaging findings of MI, combined 
with an increase in the creatine kinase myocardial band fraction (CK-MB) above the upper 
normal limits, or an increase in troponin-T/troponin-I levels above the 99th percentile of the 
upper normal limit during the follow-up period [5]. TLR was deﬁned as revascularization of 
the target lesion due to restenosis, or re-occlusion within the stent or 5 mm in and adjacent of 
the distal or proximal segment. TVR was deﬁned as revascularization of the target vessel or 
any segment of the coronary artery containing the target lesion. Non-TVR was defined as 
revascularization of any segment of the non-target coronary artery.  
 
Statistical analysis 
All statistical analyses were performed using SPSS software, version 20 (IBM; 
Armonk, NY, USA). For continuous variables, differences among the three groups were 
evaluated using the analysis of variance or the Jonckheere-Terpstra test, and post-hoc analysis 
between two groups was carried out using the Hochberg test or Dunnett-T3 test; data are 
expressed as the means ± standard deviations. For discrete variables, the differences between 
two groups among the three groups were analyzed using the χ2 test or the Fisher exact test, as 
appropriate; data are expressed as counts and percentages. Only meaningful confounding 
covariates (p < 0.001 or those having predictive values) during the multivariable Cox 
regression analysis, which are listed were included as follows: age, sex (men), left ventricular 
ejection fraction (LVEF), body mass index (BMI), systolic blood pressure (SBP), diastolic 
blood pressure (DBP), cardiopulmonary resuscitation (CPR) on admission, primary PCI, 
hypertension, diabetes mellitus (DM), dyslipidemia, blood N-terminal pro-B-type natriuretic 
peptide (NT-proBNP), serum creatinine, total cholesterol, triglyceride, low-density 
lipoprotein cholesterol (LDL-C), ASA, clopidogrel, ticagrelor, prasugrel, beta-blockers 
(BBs), calcium channel blockers (CCBs), American College of Cardiology/American Heart 
Association (ACC/AHA) lesion type B2 and C, intravascular ultrasound (IVUS), bare-metal 
stents (BMS), sirolimus-eluting stent (SES), paclitaxel-eluting stent (PES), everolimus-
eluting stents (EES), and biolimus-eluting stents (BES). Various clinical outcomes were 
estimated using the Kaplan-Meier curve analysis, and differences between groups were 
compared with the log-rank test. A two-tailed p value of < 0.05 indicated statistical 
significance. 
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Results 
Baseline clinical, laboratory, angiographic, and procedural characteristics  
Table 1 shows the baseline, laboratory, angiographic, and procedural characteristics 
of this cohort study. The study population is composed of patients who had relatively well 
preserved LVEF (mean 51.2 ± 10.9%). The number of men among the enrolled patients was 
the highest in group C. The mean ages of the patients enrolled in group A were older than the 
other groups. The frequency of primary PCI was the highest in group C. In group A, the mean 
blood levels of CK-MB, troponin-I, NT-proBNP; the prescription rates of more recently 
developed antiplatelet agents (e.g., ticagrelor, prasugrel) and CCB as the discharge 
medications; the number of CPR on admission; ACC/AHA type C lesion, the use of IVUS 
and the deployment of zotarolimus-eluting stent (ZES) were the highest. Moreover, the mean 
diameter of deployed stents was the lowest in group A. In group B, the number of cardiogenic 
shocks; the mean value of blood glucose, Hemoglobin A1c, creatinine; the number of 
clopidogrel as the discharge medication, left anterior descending coronary artery (LAD) as an 
infarct-related artery, ACC/AHA type B1; and the deployments of BMS, SES, PES, and ≥ 3-
vessel disease were the highest. The mean length of the deployed stents was the shortest in 
group B. In group C, the mean values of BMI, SBP, DBP, total cholesterol, triglyceride, LDL-
C; the prescription rate of ASA and BB as the discharge medications; the number of 
hypertensive patients, LAD as the treated vessel, ACC/AHA type B2 lesion, and EES were 
the highest. The mean number of deployed stents was not significantly different among the 
three groups. 
 
Clinical outcomes 
Table 2 shows the cumulative incidences of major clinical outcomes during the 2-
year follow-up period. After adjustment, the cumulative incidences of MACEs in group A 
(adjusted hazard ratio [aHR]: 1.337; 95% confidence interval [CI]: 1.064–1.679; p = 0.013) 
and in group B (aHR: 1.375; 95% CI: 1.149–1.646; p = 0.001) were significantly higher than 
those in group C (Table 3, Fig. 2A). The cumulative incidence of all-cause death in group A 
was significantly higher than that in group C (aHR: 1.539; 95% CI: 1.014–2.336; p = 0.043; 
Fig. 2B). The cumulative incidences of any repeat revascularization (aHR: 1.317; 95% CI: 
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1.031–1.681; p = 0.028; Fig. 2D), TLR (aHR: 1.754; 95% CI: 0.193–2.580; p = 0.004; Fig. 
2E), and TVR (aHR: 1.539; 95% CI: 1.138–2.082; p = 0.005; Fig. 2F) in group B were 
significantly higher than those in group C. However, the cumulative incidences of CD, Re-
MI, and non-TVR were similar among the three groups before and after adjustment. Table 4 
shows the independent predictors for MACEs at 2 years. LVEF < 50% (aHR: 1.146; 95% CI: 
1.019–1.289; p = 0.023), DM (aHR: 1.342; 95% CI: 1.187–1.518; p < 0.001), multivessel 
disease (aHR: 1.774; 95% CI: 1.570–2.005; p < 0.001), cardiogenic shock (aHR: 0.998; 95% 
CI: 0.996–1.000; p = 0.043), and CPR on admission (aHR: 2.240; 95% CI: 1.784–2.813; p < 
0.001) were significant independent predictors for MACEs. 
 
Discussion 
The main findings of this study are as follows: First, the cumulative incidences of 
MACEs in group A and group B were significantly higher than those in group C. Second, the 
cumulative incidence of all-cause death in group A was significantly higher than that in group 
C. Third, the cumulative incidences of any repeat revascularization, TLR, and TVR in group 
B were significantly higher than those in group C. Finally, the cumulative incidences of CD, 
Re-MI, and non-TVR were similar among the three groups before and after adjustment. 
Statins have both fundamental lipid-lowering capacity and additional pleiotropic 
actions [9]. In patients with STEMI, these pleiotropic activities include cardiovascular death, 
non-fatal MI, and coronary revascularization rate reduction capabilities [3, 10]. Even though 
the relative superiority on the long-term clinical outcome between ACEI and ARB in AMI 
patients is still debatable [11–13], RASI is recommended in patients with STEMI after PCI 
[4, 5]. In this study, the cumulative incidence of MACEs, all-cause death, Re-MI, and any 
repeat revascularization (TLR, TVR, and non-TVR) between group A and group B were 
similar. It was assumed that the major causative factors for similar results between these two 
groups are related to a shared process, such as nitric oxide (NO) production [14]. The statins’ 
pleiotropic action include the upregulation and activation of endothelial NO synthase [15], 
and the accumulated bradykinin after ACEI treatment lead to increased stimulations of the 
NO production [16]. The combination therapy of statin and RASI compensate unwanted 
effects of statin and has additive or synergistic effects on endothelial dysfunction, 
inflammation, and lipid profiles [17–19]. Furthermore, the statin plus RASI combination 
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reduced cardiovascular events more than statin alone and to a greater extent than RASI 
therapy alone [18, 20]. As expected, additional beneficial effects of the statin and RASI 
combination therapy were observed in reducing MACEs compared to that achieved with 
monotherapy alone in this study. Previous studies have shown that both the statin and the 
RASI could reduce the death rate and revascularization rate in STEMI patients [21–23]. 
Additionally, the relative superiority between these two abilities, according to the drugs, was 
suspected in this study. Figure 2B shows the Kaplan-Meier curve of all-cause death among 
the three groups. The cumulative incidence of all-cause death in group A was continuously 
higher than that in group C during the 2-year follow-up period. However, the cumulative 
incidence of all-cause death between group B and group C was statistically insignificant. In 
contrast, the cumulative incidence of total revascularization in group B was continuously 
higher than that in group C (Fig. 2D). The cumulative incidence between group A and group 
C was insignificantly different. The Kaplan-Meier curve of TLR (Fig. 2E) and TVR (Fig. 2F) 
also showed similar patterns among the three groups. Regarding the results of this study, it 
was cautiously supposed that the possibility that RASI was more likely related with mortality 
reduction rather than revascularization reduction, and statin was more likely related with 
repeat revascularization reduction rather than mortality reduction in these STEMI patients 
after successful stent implantation. In this study, independent predictors for MACEs at 2 
years were decreased LVEF (< 50%), DM, multivessel disease, cardiogenic shock, and CPR 
on admission (Table 4). Therefore, in these situations, the combination therapy of statin and 
RASI might be helpful in reducing MACEs. 
Unlike previous studies [18, 24], the present study population was composed of 
solely STEMI patients. While some previous studies [25, 26] were conducted before the 
widespread use of statin and dual antiplatelet agents, diverse kinds of statins and newly 
developed antiplatelet agents were used in this study. More than 50 high-volume University 
or community hospitals with facilities for primary PCI and onsite cardiac surgery in South 
Korea participated in this study. Therefore, this comparative study might provide meaningful 
information to interventional cardiologists regarding the importance of a statin and RASI 
combination therapy rather than a monotherapy of each drug, and some different clinical 
outcome characteristics of the statin monotherapy and RASI monotherapy compared with a 
combination therapy in STEMI patients, after successful stent implantation during a 2-year 
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follow-up period.  
 
Limitations of the study 
This study had several limitations. First, there may be some under-reporting and/or 
missed data due to limitations of registry data. Second, this study was based on medications 
at discharge, and this registry data did not include a full detailed data concerning the starting 
times of statin and RASI therapy, change of prescription doses, long-term adherence, and 
discontinuation during the follow-up period; these factors might, therefore, act as substantial 
bias in this study. Third, the achievement of target blood cholesterol level (i.e., LDL-C) was a 
critical prognostic parameter after statin therapy during the follow-up period. However,  the 
follow-up results could not presented  for these lipid profiles due to a limitation of the 
registry data, which might act as a bias. Fourth, because this study reflectsa multicenter “real-
world” clinical practice, diverse kinds and doses of statins and RASI were prescribed; all of 
which could not be adjusted during  statistical analysis, and might be another limitation of 
this study. Fifth, the selection of either monotherapy or combination therapy of statin and 
RASI after PCI was left to physician preferences; which might act as selection bias. Sixth, a  
multivariate analysis was done to strengthen the present results; variables not included in this 
registry may have affected the study outcomes. 
 
Conclusions 
In conclusion, a statin and RASI combination therapy significantly reduced the 
cumulative incidence of MACEs compared with a monotherapy of these drugs. Moreover, 
this combination therapy showed a reduced all-cause death rate compared with statin 
monotherapy, and a decreased repeat revascularization rate compared with RASI 
monotherapy. 
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Table 1. Baseline clinical, laboratory, angiographic and procedural characteristics. 
Variables 
Total 
(n = 17,414) 
Group A 
Statin alone 
(n = 2448) 
Group B 
RASI alone 
(n = 2431) 
Group C 
Statin and RASI 
(n = 12535) 
P 
Group 
A vs. B 
Group 
A vs. C 
Group 
B vs. C 
Group A vs. 
B vs. C 
Men 13337 (76.6%) 1821 (74.4%) 1842 (75.8%) 9674 (77.2%) 0.264 0.003 0.132 0.007 
Age [years] 62.2 ± 12.7 63.1 ± 12.8 62.8 ± 12.9 61.9 ± 12.6 0.439 < 0.001 0.001 < 0.001 
LVEF [%] 51.2 ± 10.9 50.5 ± 11.1 51.5 ± 10.8 51.2 ± 10.9 0.381 < 0.001 < 0.001 < 0.001 
BMI [kg/m2] 24.1 ± 3.2 23.8 ± 3.2 23.9 ± 3.3 24.2 ± 3.2 < 0.001 < 0.001 < 0.001 < 0.001 
SBP [mmHg] 12.7 ± 27.7 122.7 ± 26.1 125.6 ± 28.5 129.0 ± 27.8 < 0.001 < 0.001 < 0.001 < 0.001 
DBP [mmHg] 78.5 ± 16.8 76.0 ± 16.4 77.3 ± 16.9 79.2 ± 16.8 0.009 < 0.001 < 0.001 < 0.001 
Cardiogenic shock 972 (5.6%) 162 (6.6%) 163 (6.7%) 647 (5.2%) 0.903 0.004 0.002 0.001 
CPR on admission 561 (3.2%) 135 (5.5%) 67 (2.8%) 359 (2.9%) < 0.001 < 0.001 0.770 < 0.001 
Primary PCI 16121 (92.6%) 2256 (92.2%) 2188 (90.0%) 16677 (93.2%) 0.008 0.077 < 0.001 < 0.001 
Hypertension 7974 (45.8%) 987 (40.3%) 1129 (46.4%) 5858 (46.7%) < 0.001 < 0.001 0.792 < 0.001 
Diabetes mellitus 4179 (24.0%) 583 (23.8%) 639 (26.3%) 2957 (23.6%) 0.046 0.810 0.004 0.017 
Dyslipidemia 1832 (10.5%) 281 (11.5%) 172 (7.1%) 1379 (11.0%) < 0.001 0.491 < 0.001 < 0.001 
Previous MI 472 (2.7%) 79 (3.2%) 60 (2.5%) 333 (2.7%) 0.111 0.114 0.595 0.206 
Previous PCI 726 (4.2%) 117 (4.8%) 93 (3.8%) 516 (4.1%) 0.101 0.136 0.506 0.214 
Previous CABG 54 (0.3%) 13 (0.5%) 3 (0.1%) 38 (0.3%) 0.013 0.077 0.121 0.036 
Previous CVA 887 (5.1%) 113 (4.6%) 130 (5.3%) 644 (5.1%) 0.240 0.281 0.669 0.465 
Previous heart failure 121 (0.7%) 21 (0.9%) 30 (1.2%) 70 (0.6%) 0.208 0.081 < 0.001 0.001 
Current smokers 8381 (48.1%) 1146 (46.8%) 1160 (47.7%) 6075 (48.5%) 0.527 0.135 0.500 0.297 
CK-MB [mg/dL] 175.6 ± 238.9 190.0 ± 2736 184.1 ± 3100 171.2 ± 214.5 0.482 0.001 0.051 0.001 
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Troponin-I [ng/mL] 64.3 ± 260.2 76.7 ± 619.7 58.3 ± 88.7 63.1 ± 140.3 0.192 0.333 0.046 0.010 
Serum glucose [mg/dL] 172.1 ± 74.3 173.1 ± 76.4 176.5 ± 77.1 171.0 ± 73.3 0.128 0.207 0.001 0.013 
Hemoglobin A1c (ng/dL) 6.6 ± 2.0 6.6 ± 2.2 6.8 ± 2.9 6.5 ± 1.8 0.178 0.293 0.022 0.020 
NT-proBNP [pg/mL] 1515.8 ± 5292.7 2325.2 ± 7028.4 1789.9 ± 4633.6 1324.0 ± 3638.3 0.109 0.002 < 0.001 < 0.001 
Hs-CRP [mg/dL] 10.8 ± 60.9 9.8 ± 46.7 11.4 ± 80.4 10.9 ± 58.7 0.467 0.385 0.804 0.523 
Serum creatinine [mg/L] 1.06 ± 1.15 1.09 ± 1.54 1.12 ± 1.06 1.05 ± 1.07 0.424 0.281 0.006 < 0.001 
Total cholesterol [mg/dL] 185.0 ± 44.2 183.5 ± 44.6 176.8 ± 44.4 186.8 ± 43.8 < 0.001 0.001 < 0.001 < 0.001 
Triglyceride [mg/L] 133.8 ± 111.7 128.7 ± 100.9 126.0 ± 102.9 136.3 ± 115.2 0.361 0.001 < 0.001 < 0.001 
HDL cholesterol [mg/L] 44.1 ± 18.5 43.5 ± 16.2 44.0 ± 14.0 44.3 ± 19.6 0.242 0.041 0.446 0.008 
LDL cholesterol [mg/L] 117.4 ± 40.0 116.0 ± 38.2 110.0 ± 38.9 119.1 ± 40.4 < 0.001 < 0.001 < 0.001 < 0.001 
Discharge medications:         
ASA 17278 (99.2%) 2405 (98.2%) 2400 (98.7%) 12437 (99.5%) 0.169 < 0.001 < 0.001 < 0.001 
Clopidogrel 15711 (90.2%) 2130 (87.0%) 2346 (96.5%) 11235 (89.6%) < 0.001 < 0.001 < 0.001 < 0.001 
Ticagrelor 931 (5.3%) 170 (6.9%) 26 (1.1%) 735 (5.9%) < 0.001 0.040 < 0.001 < 0.001 
Prasugrel 576 (3.3%) 112 (4.6%) 22 (0.9%) 442 (3.5%) < 0.001 0.012 < 0.001 < 0.001 
Cilostazole 4267 (24.5%) 584 (23.9%) 604 (24.8%) 3079 (24.6%) 0.421 0.457 0.767 0.693 
BB 14594 (83.8%) 1657 (67.7%) 2064 (84.9%) 10873 (86.7%) < 0.001 < 0.001 0.015 < 0.001 
  CCB 827 (4.7%) 161 (6.6%) 117 (4.8%) 549 (4.4%) 0.008 < 0.001 0.343 < 0.001 
Infarct-related artery:         
  LM 149 (0.9%) 23 (0.9%) 14 (0.6%) 112 (0.9%) 0.143 0.825 0.117 0.265 
  LAD 9035 (51.9%) 1207 (49.3%) 1279 (52.6%) 6549 (52.2%) 0.021 0.008 0.741 0.021 
  LCx 1621 (9.3%) 242 (9.9%) 237 (9.7%) 1142 (9.1%) 0.873 0.226 0.319 0.349 
  RCA 6598 (37.9%) 976 (39.9%) 898 (36.9%) 4724 (37.7%) 0.035 0.042 0.486 0.073 
Treated vessel:         
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LM 258 (1.5%) 32 (1.3%) 29 (1.2%) 197 (1.6%) 0.719 0.329 0.161 0.273 
  LAD 10229 (58.7%) 1371 (56.0%) 1416 (58.2%) 7442 (59.4%) 0.113 0.002 0.303 0.007 
LCx 2829 (16.2%) 399 (16.3%) 392 (16.1%) 2038 (16.3%) 0.869 0.960 0.870 0.984 
RCA 7417 (42.6%) 1078 (44.0%) 1014 (41.7%) 5325 (42.5%) 0.101 0.155 0.482 0.232 
ACC/AHA lesion type:         
Type B1 2508 (14.4%) 358 (14.6%) 405 (16.7%) 1745 (13.9%) 0.050 0.360 < 0.001 0.002 
Type B2 5060 (29.1%) 615 (25.1%) 684 (28.1%) 3761 (30.0%) 0.017 < 0.001 0.065 < 0.001 
Type C 8193 (47.0%) 1232 (50.3%) 1032 (42.5%) 5929 (47.3%) < 0.001 0.006 < 0.001 < 0.001 
Extent of CAD:         
1-vessel 9078 (52.1%) 1287 (52.6%) 1220 (50.2%) 6571 (52.4%) 0.095 0.890 0.043 0.116 
2-vessel 5201(29.9%) 753 (30.8%) 737 (30.3%) 3711 (29.6%) 0.737 0.253 0.482 0.455 
≥ 3-vessel 3135 (18.0%) 408 (16.7%) 474 (19.5%) 2253 (18.0%) 0.010 0.122 0.075 0.036 
IVUS 2397 (13.8%) 371 (15.2%) 278 (11.4%) 1748 (13.9%) < 0.001 0.116 0.001 < 0.001 
OCT 29 (0.2%) 2 (0.1%) 2 (0.1%) 25 (0.2%) 0.994 0.298 0.213 0.233 
FFR 104 (0.6%) 16 (0.7%) 2 (0.1%) 86 (0.7%) 0.001 0.858 < 0.001 0.002 
Types of stent:         
  BMS 1127 (6.5%) 105 (4.3%) 185 (7.6%) 837 (6.7%) < 0.001 < 0.001 0.095 < 0.001 
  SES 2865 (16.5%) 376 (15.4%) 558 (23.0%) 1931 (15.4%) < 0.001 0.955 < 0.001 < 0.001 
PES 2446 (14.0%) 313 (12.8%) 466 (19.2%) 1667 (13.3%) < 0.001 0.493 < 0.001 < 0.001 
  ZES 3869 (22.2%) 585 (23.9%) 486 (20.0%) 2798 (22.3%) 0.001 0.088 0.011 0.004 
  EES 4754 (27.3%) 693 (28.3%) 480 (19.7%) 3581 (28.6%) < 0.001 0.795 < 0.001 < 0.001 
  BES 1343 (7.7%) 203 (8.3%) 100 (4.1%) 1040 (8.3%) < 0.001 0.994 < 0.001 < 0.001 
Stent diameter [mm] 3.20 ± 0.42 3.18 ± 0.44 3.20 ± 0.42 3.20 ± 0.42 0.044 0.008 0.956 0.007 
Stent length [mm] 25.9 ± 9.0 26.1 ± 9.4 24.8 ± 7.0 26.1 ± 9.2 < 0.001 0.973 < 0.001 0.011 
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Number of stent 1.40 ± 0.72 1.40 ± 0.71 1.38 ± 0.70 1.41 ± 0.73 0.511 0.430 0.100 0.222 
Values are means ± standard deviation or numbers and percentages. The p value for continuous data was obtained from the analysis of variance or the Jonckheere-Terpstra 
test. The p value for categorical data was obtained from the chi-square or the Fisher’s exact test. Group A — statin alone; Group B — RASI alone; Group C — both statin 
and RASI; LVEF — left ventricular ejection fraction; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; CPR — 
cardiopulmonary resuscitation; PCI — percutaneous coronary intervention; MI — myocardial infarction; CABG — coronary artery bypass grafting; CVA — 
cerebrovascular accidents; CK-MB — creatinine kinase myocardial band; NT-proBNP — N-terminal pro-B-type natriuretic peptide; Hs-CRP — high sensitivity C-
reactive protein; HDL — high-density lipoprotein; LDL — low-density lipoprotein; ASA — acetylsalicylic acid; BB — beta-blockers; CCB — calcium channel blockers; 
LM — left main coronary artery; LAD — left anterior descending coronary artery; LCx — left circumflex coronary artery; RCA — right coronary artery; ACC/AHA — 
American College of Cardiology/American Heart Association; CAD — coronary artery disease; IVUS — intravascular ultrasound; OCT — optical coherence 
tomography; FFR — fractional flow reserve; BMS — bare-metal stents; SES — sirolimus-eluting stents; PES — paclitaxel-eluting stents; ZES — zotarolimus-eluting 
stents; EES — everolimus-eluting stents; BES — biolimus-eluting stents 
 
Table 2. Cumulative clinical events at 2 years. 
Variables 
Total  
(n = 17,414) 
Group A 
(n = 2448) 
Group B 
(n = 2431) 
Group C 
(n = 12,535) 
P 
Group A vs. 
B 
Group A vs. 
C 
Group B vs. 
C 
Group A vs. 
B vs. C 
MACEs  1262 (7.2%) 193 (7.9%) 214 (8.8%) 855 (6.8%) 0.246 0.059 0.001 0.001 
All-cause death: 358 (2.1%) 67 (2.7%) 59 (2.4%) 232 (1.9%) 0.528 0.004 0.060 0.007 
   Cardiac death 248 (1.4%) 44 (1.8%) 39 (1.6%) 165 (1.3%) 0.602 0.063 0.262 0.133 
Re-MI: 257 (1.5%) 44 (1.8%) 32 (1.3%) 181 (1.4%) 0.175 0.188 0.627 0.324 
Any repeat revascularization: 737 (4.2%) 94 (3.8%) 136 (5.6%) 507 (4.0%) 0.004 0.637 0.001 0.001 
   TLR 246 (1.4%) 34 (1.4%) 52 (2.1%) 160 (1.3%) 0.046 0.653 0.001 0.004 
TVR 426 (2.4%) 50 (2.0%) 82 (3.4%) 294 (2.3%) 0.004 0.360 0.003 0.004 
Non-TVR 323 (1.9%) 44 (1.8%) 57 (2.3%) 222 (1.8%) 0.179 0.928 0.056 0.155 
Values are means ± standard deviation or numbers and percentages. The p values for categorical data were obtained from chi-square or Fisher’s exact test. Group A — 
statin alone; Group B — RASI alone; Group C — both statin and RASI; MACEs — major adverse cardiac events; Re-MI — recurrent myocardial infarction; TLR — 
target lesion revascularization; TVR — target vessel revascularization  
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Table 3. Hazard ratio for 2-year major clinical outcomes by Cox-proportional hazard ratio analysis.  
                Hazard ratio (95% confidence interval), P 
 Group A vs. B Group A vs. C Group B vs. C 
MACE:    
   Unadjusted  1.057 (0.870–1.285), 0.574 1.187 (1.016–1.388), 0.031 1.256 (1.081–1.459), 0.003 
   Adjusted* 1.093 (0.822–1.454), 0.540 1.337 (1.064–1.679), 0.013 1.375 (1.149–1.646), 0.001 
All-cause death:    
   Unadjusted  1.185 (0.835–1.681), 0.343 1.506 (1.148–1.977), 0.003 1.275 (0.958–1.696), 0.096 
   Adjusted* 1.386 (0.803–2.390), 0.241 1.539 (1.014–2.336), 0.043 1.172 (0.767–1.793), 0.463 
Cardiac death:    
   Unadjusted 1.164 (0.756–1.792), 0.490 1.386 (0.994–1.933), 0.054 1.192 (0.841–1.690), 0.323 
   Adjusted* 1.125 (0.528–2.394), 0.768 1.090 (0.609–1.951), 0.772 1.244 (0.726–2.131), 0.426 
Re-MI:    
   Unadjusted  1.434 (0.910–2.262), 0.121 1.276 (0.918–1.774), 0.147 1.135 (0.779–1.652), 0.510 
   Adjusted  1.048 (0.528–2.081), 0.894 1.041 (0.637–1.699), 0.873 1.180 (0.725–1.921), 0.499 
Any repeat revascularization:    
   Unadjusted 1.377 (1.059–1.791), 0.017 1.024 (0.822–1.276), 0.831 1.345 (1.113–1.625), 0.002 
   Adjusted* 1.038 (0.712–1.513), 0.847 1.263 (0.926–1.722), 0.141 1.317 (1.031–1.681), 0.028 
TLR:    
   Unadjusted  1.450 (0.941–2.234), 0.092 1.119 (0.773–1.620), 0.119 1.624 (0.188–2.221), 0.002 
   Adjusted* 1.111 (0.618–1.998), 0.724 1.648 (0.999–2.717), 0.050 1.754 (0.193–2.580), 0.004 
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TVR:    
   Unadjusted 1.555 (1.094–2.210), 0.014 1.116 (0.827–1.506), 0.474 1.391 (1.089–1.777), 0.008 
   Adjusted* 1.184 (0.736–1.905), 0.487 1.286 (0.857–1.930), 0.224 1.539 (1.138–2.082), 0.005 
Non-TVR:    
   Unadjusted  1.230 (0.830–1.823), 0.302 1.004 (0.755–1.442), 0.796 1.284 (0.960–1.718), 0.092 
   Adjusted*  1.067 (0.578–1.968), 0.836 1.166 (0.721–1.886), 0.531 1.074 (0.717–1.610), 0.729 
*Adjusted model was included age, gender (men), LVEF, BMI, SBP, DBP, CPR on admission, primary PCI, hypertension, DM, dyslipidemia, N-proBNP, serum 
creatinine, total cholesterol, triglyceride, LDL-cholesterol, ASA, clopidogrel, ticagrelor, prasugrel, BB, CCB, ACC/AHA lesion type B2 and C, IVUS, BMS, SES, PES, 
EES, BES. Abbreviations — see Table 1 
 
Table 4. Multivariate Cox-proportional regression analysis for independent predictor of MACEs  
Variables 
Unadjusted  Adjusted  
HR (95% CI) P HR (95% CI) P 
Groups     
   Group A vs. B 1.057 (0.870–1.285) 0.574 1.063 (0.870–1.298) 0.550 
   Group A vs. C 1.187 (1.016–1.388) 0.031 1.208 (1.037–1.408) 0.019 
   Group B vs. C 1.256 (1.081–1.459) 0.003 1.217 (1.044–1.418) 0.012 
Age, ≥ 65 years 1.042 (1.013–1.071) 0.004 1.034 (0.990–1.081) 0.129 
Gender, men 1.208 (1.066–1.367) 0.003 1.038 (0.899–1.199) 0.281 
LVEF, < 50% 1.248 (1.118–1.394) < 0.001 1.146 (1.019–1.289) 0.023 
Hypertension 1.211 (1.084–1.352) 0.001 1.082 (0.961–1.217) 0.192 
Diabetes mellitus 1.481 (1.315–1.667) < 0.001 1.342 (1.187–1.518) < 0.001 
Dyslipidemia 1.066 (0.894–1.271) 0.478 1.027 (0.857–1.232) 0.772 
Previous MI 1.373 (1.020–1.849) 0.037 1.206 (0.890–1.633) 0.227 
Multi-vessel disease 1.897 (1.691–2.129) < 0.001 1.774 (1.570–2.005) < 0.001 
Current smokers 1.145 (1.025–1.279) 0.017 1.043 (0.869–1.251) 0.842 
Cardiogenic shock 1.301 (1.049–1.614) 0.017 1.135 (0.908–1.419) 0.043 
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CPR on admission 2.385 (1.941–2.972) < 0.001 2.240 (1.784–2.813) < 0.001 
ACC/AHA type B2/C 1.027 (0.902–1.168) 0.689 1.028 (0.900–1.174) 0.701 
Stent diameter, < 3.0 mm 1.242 (1.093–1.412) 0.001 1.116 (0.978–1.273) 0.103 
Stent length, ≥ 28 mm 1.149 (1.027–1.285) 0.015 1.048 (0.934–1.176) 0.421 
LAD–IRA 1.002 (0.898–1.119) 0.967 1.072 (0.881–1.305) 0.541 
LAD — treated vessel 1.158 (1.034–1.298) 0.011 1.190 (0.978–1.447) 0.083 
IVUS 1.117 (0.956–1.307) 0.164 1.083 (0.923–1.271) 0.329 
HR — hazard ratio; CI — confidence interval; IRA — infarct-related artery; other abbreviations — see Table 1 
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Figure 1. Flow chart; KAMIR — Korea Acute myocardial Infarction Registry; STEMI — 
ST-segment elevation myocardial infarction; RAMI — renin–angiotensin system inhibitor. 
 
Figure 2. Kaplan-Meier curved analysis for major adverse cardiac events (MACEs; A), all-
cause death (B), recurrent myocardial infarction (Re-MI; C), any repeat revascularization 
(D), target lesion revascularization (TLR; E), and target vessel revascularization (TVR; F) 
during a 2-year follow-up period. 




